RU2698911C2 - Композиции, содержащие антитела к cd38 и леналидомид - Google Patents

Композиции, содержащие антитела к cd38 и леналидомид Download PDF

Info

Publication number
RU2698911C2
RU2698911C2 RU2015127089A RU2015127089A RU2698911C2 RU 2698911 C2 RU2698911 C2 RU 2698911C2 RU 2015127089 A RU2015127089 A RU 2015127089A RU 2015127089 A RU2015127089 A RU 2015127089A RU 2698911 C2 RU2698911 C2 RU 2698911C2
Authority
RU
Russia
Prior art keywords
lenalidomide
antibody
compound
antibodies
seq
Prior art date
Application number
RU2015127089A
Other languages
English (en)
Russian (ru)
Other versions
RU2015127089A (ru
Inventor
Байрон К. ХАНН
III Томас Г. МАРТИН
Блейк Т. АФТАБ
Блейк Томкинсон
Original Assignee
Санофи
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи, Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния filed Critical Санофи
Publication of RU2015127089A publication Critical patent/RU2015127089A/ru
Application granted granted Critical
Publication of RU2698911C2 publication Critical patent/RU2698911C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2015127089A 2012-12-07 2013-12-06 Композиции, содержащие антитела к cd38 и леналидомид RU2698911C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261734524P 2012-12-07 2012-12-07
US61/734,524 2012-12-07
US201361769247P 2013-02-26 2013-02-26
US61/769,247 2013-02-26
US201361808372P 2013-04-04 2013-04-04
US61/808,372 2013-04-04
PCT/US2013/073540 WO2014089416A1 (en) 2012-12-07 2013-12-06 Compositions comprising anti-cd38 antibodies and lenalidomide

Publications (2)

Publication Number Publication Date
RU2015127089A RU2015127089A (ru) 2017-01-13
RU2698911C2 true RU2698911C2 (ru) 2019-09-02

Family

ID=50884019

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015127089A RU2698911C2 (ru) 2012-12-07 2013-12-06 Композиции, содержащие антитела к cd38 и леналидомид

Country Status (31)

Country Link
EP (2) EP2928495B1 (cg-RX-API-DMAC7.html)
JP (2) JP6499971B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200143503A (cg-RX-API-DMAC7.html)
CN (1) CN105263520B (cg-RX-API-DMAC7.html)
AR (1) AR093844A1 (cg-RX-API-DMAC7.html)
AU (2) AU2013355064B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015012987A2 (cg-RX-API-DMAC7.html)
CA (1) CA2893946A1 (cg-RX-API-DMAC7.html)
CL (2) CL2015001558A1 (cg-RX-API-DMAC7.html)
CY (2) CY1122478T1 (cg-RX-API-DMAC7.html)
DK (1) DK2928495T3 (cg-RX-API-DMAC7.html)
ES (1) ES2731548T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191034T1 (cg-RX-API-DMAC7.html)
HU (3) HUE044142T2 (cg-RX-API-DMAC7.html)
IL (2) IL239234B (cg-RX-API-DMAC7.html)
LT (2) LT2928495T (cg-RX-API-DMAC7.html)
LU (1) LUC00187I2 (cg-RX-API-DMAC7.html)
MX (2) MX366296B (cg-RX-API-DMAC7.html)
MY (1) MY191601A (cg-RX-API-DMAC7.html)
NL (1) NL301079I2 (cg-RX-API-DMAC7.html)
NZ (1) NZ709215A (cg-RX-API-DMAC7.html)
PH (1) PH12015501263A1 (cg-RX-API-DMAC7.html)
PL (1) PL2928495T3 (cg-RX-API-DMAC7.html)
PT (1) PT2928495T (cg-RX-API-DMAC7.html)
RS (1) RS58829B1 (cg-RX-API-DMAC7.html)
RU (1) RU2698911C2 (cg-RX-API-DMAC7.html)
SG (3) SG10201913783PA (cg-RX-API-DMAC7.html)
SI (1) SI2928495T1 (cg-RX-API-DMAC7.html)
TW (2) TW201919699A (cg-RX-API-DMAC7.html)
UA (1) UA118255C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014089416A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
WO2015195555A1 (en) * 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
PE20181323A1 (es) 2015-06-22 2018-08-14 Janssen Biotech Inc Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US11613586B2 (en) 2016-07-15 2023-03-28 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
WO2019140410A1 (en) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
WO2019199133A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드의 경구용 코팅 정제 조성물
KR102286497B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 다양한 용량의 레날리도마이드의 경구용 정제 조성물
KR102286500B1 (ko) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물
WO2019199135A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 경구용 고형제제의 제조방법
CN120285175A (zh) 2018-05-16 2025-07-11 詹森生物科技公司 治疗癌症并增强t细胞重定向治疗剂的功效的方法
EP3860610A4 (en) * 2018-10-01 2022-06-15 Celgene Corporation COMBINATION THERAPY FOR THE TREATMENT OF CANCER
MX2021011181A (es) * 2019-03-15 2022-01-19 Morphosys Ag Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos.
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
EP3980064A1 (en) * 2019-06-10 2022-04-13 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
IL317199A (en) * 2019-10-31 2025-01-01 Morphosys Ag Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
AU2020397170A1 (en) 2019-12-05 2022-07-21 Sanofi-Aventis U.S. Llc Formulations of anti-CD38 antibodies for subcutaneous administration
US20250277051A1 (en) * 2021-08-02 2025-09-04 Hangzhou Unogen Biotech, Ltd Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148449A1 (en) * 2005-03-23 2009-06-11 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20100092489A1 (en) * 2006-09-26 2010-04-15 Genmab A/S Combination treatment of cd38-expressing tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN101084252B (zh) * 2004-12-21 2012-06-13 日本化药株式会社 环氧树脂、环氧树脂组合物及其固化物
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
KR101912957B1 (ko) * 2010-09-27 2018-10-29 모르포시스 아게 다발성 골수종 및 nhl 치료를 위한 항-cd38 항체 및 레날리도마이드 또는 보르테조밉
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148449A1 (en) * 2005-03-23 2009-06-11 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20100092489A1 (en) * 2006-09-26 2010-04-15 Genmab A/S Combination treatment of cd38-expressing tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KLEIN U. et al., Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone, Ann Hematol. 2009 Jan; 88(1):67-71. doi: 10.1007/s00277-008-0561-1. Epub 2008 Jul 31 - . *
VAN DER VEER M. S. et al., Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab, Haematologica. 2011 Feb; 96(2):284-90. doi: 10.3324/haematol.2010.030759. Epub 2010 Nov 25. *
VAN DER VEER M. S. et al., Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab, Haematologica. 2011 Feb; 96(2):284-90. doi: 10.3324/haematol.2010.030759. Epub 2010 Nov 25. KLEIN U. et al., Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone, Ann Hematol. 2009 Jan; 88(1):67-71. doi: 10.1007/s00277-008-0561-1. Epub 2008 Jul 31 - реферат. *

Also Published As

Publication number Publication date
SG10201913783PA (en) 2020-03-30
EP2928495A1 (en) 2015-10-14
CY2020040I1 (el) 2021-03-12
KR102193045B1 (ko) 2020-12-18
HRP20191034T1 (hr) 2019-08-23
CY1122478T1 (el) 2021-01-27
CN105263520B (zh) 2020-03-13
CL2015001558A1 (es) 2015-10-02
HUE044142T2 (hu) 2019-09-30
SG11201504315WA (en) 2015-07-30
CN105263520A (zh) 2016-01-20
AU2013355064B2 (en) 2018-05-24
MX2015007189A (es) 2016-03-21
IL282542A (en) 2021-06-30
HK1215536A1 (en) 2016-09-02
DK2928495T3 (da) 2019-06-24
RS58829B1 (sr) 2019-07-31
MX366296B (es) 2019-07-04
KR20150091165A (ko) 2015-08-07
EP2928495A4 (en) 2016-05-11
CA2893946A1 (en) 2014-06-12
LT2928495T (lt) 2019-07-10
HUS2000050I1 (hu) 2020-12-28
LTPA2020537I1 (lt) 2020-12-28
SG10201704536PA (en) 2017-07-28
JP6499971B2 (ja) 2019-04-10
EP2928495B1 (en) 2019-03-27
BR112015012987A2 (pt) 2017-09-12
SI2928495T1 (sl) 2019-07-31
IL239234A0 (en) 2015-07-30
ES2731548T3 (es) 2019-11-15
HUS2000051I1 (hu) 2020-12-28
RU2015127089A (ru) 2017-01-13
PL2928495T3 (pl) 2019-09-30
JP2016506388A (ja) 2016-03-03
AR093844A1 (es) 2015-06-24
MY191601A (en) 2022-07-01
LTC2928495I2 (lt) 2024-11-25
WO2014089416A1 (en) 2014-06-12
KR20200143503A (ko) 2020-12-23
PH12015501263A1 (en) 2015-08-17
AU2013355064A1 (en) 2015-07-09
MX2019008065A (es) 2019-09-23
CL2018003292A1 (es) 2019-02-01
NL301079I2 (nl) 2021-03-29
TW201427663A (zh) 2014-07-16
AU2018211258A1 (en) 2018-08-16
EP3597191A1 (en) 2020-01-22
UA118255C2 (uk) 2018-12-26
CY2020040I2 (el) 2021-05-05
LUC00187I2 (cg-RX-API-DMAC7.html) 2024-07-01
TWI670062B (zh) 2019-09-01
IL239234B (en) 2021-05-31
NZ709215A (en) 2020-08-28
JP2019070020A (ja) 2019-05-09
PT2928495T (pt) 2019-07-04
TW201919699A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
RU2698911C2 (ru) Композиции, содержащие антитела к cd38 и леналидомид
US10342869B2 (en) Compositions comprising anti-CD38 antibodies and lenalidomide
RU2670127C2 (ru) Композиции, включающие антитела к cd38 и карфилзомиб
HK1215536B (en) Compositions comprising anti-cd38 antibodies and lenalidomide
HK1219897B (en) Compositions comprising anti-cd38 antibodies and carfilzomib